Address: 4, rue Pierre Fontaine, F 91000 Evry, France
Tel: +33 1 60 87 89 80
Fax: +33 1 60 87 89 62


XenTech is an innovative biotech/CRO company specialising in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets.

XenTech is an independent privately owned research company founded in 2006 as a spin off of Institut Curie.

We offer a unique collection of patient-derived tumor xenografts (PDX). PDX closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.

Our PDX models are extensively characterized and are associated to molecular data including gene expression and copy number data. The collection is representative of the major types of solid cancer:

  • breast cancer (the world’s largest panel of breast cancer PDX)
  • Lung cancer
  • Colon cancer
  • prostatecancer
  • melanoma
  • ovarian cancer
  • pancreatic cancer
  • glioma
  • hepatoblastoma

Our preclinical platform is of considerable value for translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine.

XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research.

XenTech is known worldwide for its renowned oncology translational platform, its unique panel of patient-derived breast cancer xenografts and its extremely experienced scientific team.

We are located in the south of Paris, at Genopole Campus.


To learn more about XenTech's services and capabilities and how they can assist your business, please contact XenTech directly.

Follow us on:
Follow Us Networking
  • Drug Discovery
  • Pre-Clinical Research